Masimo Co. (NASDAQ:MASI – Get Free Report) Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Masimo Stock Performance
MASI opened at $168.21 on Monday. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.04. The company has a fifty day moving average of $174.84 and a 200 day moving average of $157.94. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.
Masimo (NASDAQ:MASI – Get Free Report) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Masimo
Wall Street Analyst Weigh In
Several research analysts have weighed in on MASI shares. Wells Fargo & Company increased their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.
Check Out Our Latest Stock Report on Masimo
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Featured Stories
- Five stocks we like better than Masimo
- What is the S&P 500 and How It is Distinct from Other Indexes
- How to Build the Ultimate Everything ETF Portfolio
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Trading Halts Explained
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.